Background: Since 1981, we have used the term metabolic syndrome to describe an association of a dysregulation in lipid metabolism (high triglycerides, low high-density lipoprotein cholesterol, disturbed glucose homeostasis (enhanced fasting and/or prandial glucose), gout, and hypertension), with android obesity being based on a common soil (overnutrition, reduced physical activity, sociocultural factors, and genetic predisposition). We hypothesized that main traits of the syndrome occur early and are tightly connected with hyperinsulinemia/insulin resistance, procoagulation, and cardiovascular diseases. Methods: To establish a close link between the traits of the metabolic vascular syndrome, we focused our literature search on recent original work and comprehensive reviews dealing with the topics metabolic syndrome, visceral obesity, fatty liver, fat tissue inflammation, insulin resistance, atherogenic dyslipidemia, arterial hypertension, and type 2 diabetes mellitus. Results: Recent research supports the concept that the metabolic vascular syndrome is a multidimensional and interactive network of risk factors and diseases based on individual genetic susceptibility and epigenetic changes where metabolic dysregulation/metabolic inflexibility in different organs and vascular dysfunction are early interconnected. Conclusion: The metabolic vascular syndrome is not only a risk factor constellation but rather a life-long abnormality of a closely connected interactive cluster of developing diseases which escalate each other and should continuously attract the attention of every clinician.

Keywords:
Metabolic syndrome, Metabolic vascular syndrome, Obesity, Insulin resistance, Type 2 diabetes, Common soil
1.
Hanefeld M, Leonhardt W: Das metabolische Syndrom. Dt Gesundheitswesen 1981;36:545-551.
2.
Hanefeld M, Koehler C, Gallo S, Benke I, Ott P: Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007;6:13.
3.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. American Heart Association; National Heart, Lung, and Blood Institute. Circulation 2005;112:2735-2752.
4.
Fachkommission Diabetes Sachsen, Saxony, Germany: Practical Guideline Metabolic Vascular Syndrome. 1st edition: 2007; 2nd edition: 2013.
5.
Scholz GH: BOT-Basal(insulin) unterstützte orale Therapie bei Diabetes mellitus Typ 2 - Pathophysiologisch begründete Therapie bei Metabolisch-Vaskulärem Syndrom (MVS). Bremen, UNI-MED, 2010.
6.
Hanefeld M, Pistrosch F, Bornstein SR, Birkenfeld AL: The metabolic vascular syndrome - guide to an individualized treatment. Rev Endocr Metab Disord 2016;17:5-17.
7.
Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, Lee WC, Kang MI, Yim HW, Yoon KH, Son HY: Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig 2013;4:334-343.
8.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
9.
Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
10.
DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
11.
Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001;226:13-26.
12.
Samuel VT, Shulman GI: The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016;126:12-22.
13.
Brown MS, Goldstein JL: Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008;7:95-96.
14.
Li S, Brown MS, Goldstein JL: Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010;107:3441-3446.
15.
Titchenell PM, Quinn WJ, Lu M, Chu Q, Lu W, Li C, Chen H, Monks BR, Chen J, Rabinowitz JD, Birnbaum MJ: Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab 2016;23:1154-1166.
16.
Tan SX, Fisher-Wellman KH, Fazakerley DJ, Ng Y, Pant H, Li J, Meoli CC, Coster AC, Stöckli J, James DE: Selective insulin resistance in adipocytes. J Biol Chem 2015;290:11337-11348.
17.
Schmidt V, Schulz N, Yan X, Schürmann A, Kempa S, Kern M, Blüher M, Poy MN, Olivecrona G, Willnow TE: SORLA facilitates insulin receptor signaling in adipocytes and exacerbates obesity. J Clin Invest 2016;126:2706-2720.
18.
Kumari M, Wang X, Lantier L, Lyubetskaya A, Eguchi J, Kang S, Tenen D, Roh HC, Kong X, Kazak L, Ahmad R, Rosen ED: IRF3 promotes adipose inflammation and insulin resistance and represses browning. J Clin Invest 2016;126:2839-2854.
19.
Jiao P, Ma J, Feng B, Zhang H, Diehl JA, Chin YE, Yan W, Xu H: FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKKβ pathways. Obesity (Silver Spring) 2011;19:483-491.
20.
Vergoni B, Cornejo PJ, Gilleron J, Dedjani M, Ceppo F, Jacquel A, Bouget G, Ginet C, Gonzalez T, Maillet J, Dhennin V, Verbanck M, Auberger P, Froguel P, Tanti JF, Cormont M: DNA damage and the activation of the p53 pathway mediate alterations in metabolic and secretory functions of adipocytes. Diabetes 2016;DOI: 10.2337/db16-0014.
21.
King GL, Park K, Li Q: Selective insulin resistance and the development of cardiovascular diseases in diabetes: the 2015 Edwin Bierman Award Lecture. Diabetes 2016; 65:1462-1471.
22.
Cefalu WT: ‘Prediabetes': are there problems with this label? No, we need heightened awareness of this condition! Diabetes Care 2016;39:1472-1477.
23.
Yudkin JS: ‘Prediabetes': are there problems with this label? Yes, the label creates further problems! Diabetes Care 2016;39:1468-1471.
24.
Scherer PE: The multifaceted roles of adipose tissue-therapeutic targets for diabetes and beyond: the 2015 Banting Lecture. Diabetes 2016;65:1452-1461.
25.
Sims EA: Are there persons who are obese, but metabolically healthy? Metabolism 2001;12:1499-1504.
26.
Blüher M: The distinction of metabolically ‘healthy' from ‘unhealthy' obese individuals. Curr Opin Lipidol 2010;1:38-43.
27.
Muñoz-Garach A, Cornejo-Pareja I, Tinahones FJ: Does metabolically healthy obesity exist? Nutrients 2016;8:pii: E320.
28.
Zheng R, Liu C, Wang C, Zhou B, Liu Y, Pan F, Zhang R, Zhu Y: Natural course of metabolically healthy overweight/obese subjects and the impact of weight change. Nutrients 2016;8:pii: E430.
29.
Gonçalves CG, Glade MJ, Meguid MM: Metabolically healthy obese individuals: key protective factors. Nutrition 2016;32:14-20.
30.
Rydén M, Hrydziuszko O, Mileti E, et al: The adipose transcriptional response to insulin is determined by obesity, not insulin sensitivity. Cell Rep 2016;16:2317-2326.
31.
Lopes HF, Corrêa-Giannella ML, Consolim-Colombo FM, Egan BM: Visceral adiposity syndrome. Diabetol Metab Syndr 2016;8:40.
32.
Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, Fallah P, Bazi Z: Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag 2015;11:55-70.
33.
Jornayvaz FR, Shulman GI: Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab 2012;15:574-584.
34.
Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867.
35.
Blüher M: Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance. Clinical Science 2016;130:1603-1614.
36.
Moreno-Indias I, Tinahones FJ: Impaired adipose tissue expandability and lipogenic capacities as one of the main causes of metabolic disorders. J Diabetes Res 2015;2015:970375.
37.
Blüher M: Adipose tissue dysfunction contributes to obesity-related metabolic diseases. Best Pract Res Clin Endocrinol Metab 2013;27:163-177.
38.
Seven E, Husemoen LL, Sehested TS, Ibsen H, Wachtell K, Linneberg A, Jeppesen JL: Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study. PLoS One 2015;10: e0128987.
39.
Wolk R, Bertolet M, Singh P, Brooks MM, Pratley RE, Frye RL, Mooradian AD, Rutter MK, Calvin AD, Chaitman BR, Somers VK; BARI 2D Study Group: Prognostic value of adipokines in predicting cardiovascular outcome: explaining the obesity paradox. Mayo Clin Proc 2016;91:858-866.
40.
Wu ZJ, Cheng YJ, Gu WJ, Aung LH: Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism 2014;63:1157-1166.
41.
Ortega Moreno L, Copetti M, Fontana A, De Bonis C, Salvemini L, Trischitta V, Menzaghi C: Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc Diabetol 2016;15:17.
42.
Gotoda T: Another paradox regarding adiponectin revisited. J Atheroscler Thromb 2016;23:292-294.
43.
Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253-1261.
44.
Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, Mueller H, de Wiza DH, Floerke RR, Smiris K, Lamb HJ, de Roos A, Bax JJ, Romijn JA, Smit JW, Akhyari P, Lichtenberg A, Eckel J, Diamant M, Ouwens DM: Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013;8:e59697.
45.
Tan YL, Zheng XL, Tang CK: The protective functions of omentin in cardiovascular diseases. Clin Chim Acta 2015;448:98-106.
46.
Du Y, Ji Q, Cai L, Huang F, Lai Y, Liu Y, Yu J, Han B, Zhu E, Zhang J, Zhou Y, Wang Z, Zhao Y: Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovasc Diabetol 2016;15:90.
47.
Saely CH, Leiherer A, Muendlein A, Vonbank A, Rein P, Geiger K, Malin C, Drexel H: Coronary patients with high plasma omentin are at a higher cardiovascular risk. Data Brief 2015;6:158-161.
48.
Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM: Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995;1:1155-1161.
49.
Scholz GH, Englaro P, Thiele I, Scholz M, Klusmann T, Kellner K, Rascher W, Blum WF: Dissociation of serum leptin concentration and body fat content during long term dietary intervention in obese individuals. Horm Metab Res 1996;28:718-723.
50.
Friedman JM, Mantzoros CS: 20 years of leptin: from the discovery of the leptin gene to leptin in our therapeutic armamentarium. Metabolism 2015;64:1-4.
51.
Xue B, Yu Y, Zhang Z, Guo F, Beltz TG, Thunhorst RL, Felder RB, Johnson AK: Leptin mediates high-fat diet sensitization of angiotensin II-elicited hypertension by upregulating the brain renin-angiotensin system and inflammation. Hypertension 2016;67:970-976.
52.
Tsay YC, Chen CH, Pan WH: Ages at onset of 5 cardiometabolic diseases adjusting for nonsusceptibility: implications for the pathogenesis of metabolic syndrome. Am J Epidemiol 2016;184:366-377.
53.
Schwartz SS, Epstein S, Corkey BE, Grant SF, Gavin JR 3rd, Aguilar RB: The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care 2016;39:179-186.
54.
Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF: Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes 2016;65:1767-1778.
55.
Ecelbarger CM: Metabolic syndrome, hypertension, and the frontier between. Am J Physiol Renal Physiol 2016;310:F1175-1177.
56.
Frigolet ME, Torres N, Tovar AR: The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 2013;24:2003-2015.
57.
Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR: Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003;100:14211-14216.
58.
Vleugels K, Schinner S, Krause D, Morawietz H, Bornstein SR, Ehrhart-Bornstein M, Krug AW: ERK1/2 MAPKs and Wnt signaling pathways are independently involved in adipocytokine-mediated aldosterone secretion. Exp Clin Endocrinol Diabetes 2011;119:644-648.
59.
O'Seaghdha CM1, Hwang SJ, Vasan RS, Larson MG, Hoffmann U, Wang TJ, Fox CS: Correlation of renin angiotensin and aldosterone system activity with subcutaneous and visceral adiposity: the Framingham Heart Study. BMC Endocr Disord 2012;12:3.
© 2016 S. Karger GmbH, Freiburg
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.